KYIV. Feb 16 (Interfax-Ukraine) – Biofarma pharmaceutical company (Kyiv region) plans to retain investment in its development in 2016 at the level of 2015 – $12 million.
“In general, in 2015 our investment reached $12 million. We plan not the smaller sum for 2016,” Board Chairman Kostiantyn Yefymenko told Interfax-Ukraine.
He said that last year Biofarma invested $5 million in construction of a probiotic workshop, $3 million in reconstruction of the Sumy blood donor center and $2 million was invested in designing of new medicines.
In addition, Yefymenko said that in 2015 Biofarma renewed the marketing and sales service.
“Now persons with experience of work in famous international corporations are among our top managers. Today this is important as in 2015 we introduced some new medicines to the market and we’re preparing new forms of our products, including nasal sprays, eye drops and suppositories. Probiotics have been launched to the active promotion,” he said.
Yefymenko said that blood preparations are a top-priority direction for the company. In money terms revenue from their sales is 40%.
Biofarma is among the ten largest Ukrainian drug manufactures. Biofarma produces more than 20 immunobiological preparations of blood, as well as drugs obtained by recombinant DNA technology and probiotics.
Niobera Investments Limited (Cyprus) holds 100% in Biofarma. According to the National Commission for Securities and the Stock Market of Ukraine, Biofarma Board Chairman Kostiantyn Yefymenko is the ultimate beneficiary of a large shareholder in Niobera Investments Limited. Shares do not belong to members of the executive body.
In 2014, Biofarma built a pharmaceutical plant in Bila Tserkva (Kyiv region). Investment totaled $42 million.
In 2014, Biofarma cut its net profit by 9.91% from a year ago, to UAH 25.801 million.
